Trials / Conditions / Primary IgA Nephropathy

Primary IgA Nephropathy

20 registered clinical trials studyying Primary IgA Nephropathy — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study of YKST02 in Participants With Primary IgA Nephropathy NCT07498673	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	EARLY_Phase 1
Not Yet Recruiting	A Study of SHR-2173 in Participants With Primary IgA Nephropathy NCT07354932	Guangdong Hengrui Pharmaceutical Co., Ltd	Phase 2
Recruiting	A Trial of HRS-5965 Capsule in Primary IgA Nephropathy NCT07014826	Chengdu Suncadia Medicine Co., Ltd.	Phase 3
Not Yet Recruiting	Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy NCT06982040	Nanjing Chia-tai Tianqing Pharmaceutical	Phase 2
Active Not Recruiting	A Trial of HRS-5965 Tablets in Primary IgA Nephropathy NCT06137768	Chengdu Suncadia Medicine Co., Ltd.	Phase 2
Recruiting	A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobu NCT05797610	Hoffmann-La Roche	Phase 3
Terminated	Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy NCT05847920	Guangdong Hengrui Pharmaceutical Co., Ltd	Phase 2
Active Not Recruiting	A Study of Telitacicept for IgA Nephropathy (TELIGAN) NCT05799287	RemeGen Co., Ltd.	Phase 3
Completed	Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN NCT06589752	Ruijin Hospital	—
Recruiting	A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/L NCT04557462	Novartis Pharmaceuticals	Phase 3
Completed	A Trial of HR19042 Capsule in Healthy Chinese Subjects NCT04887532	Jiangsu HengRui Medicine Co., Ltd.	Phase 1
Completed	Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE) NCT04541043	Calliditas Therapeutics AB	Phase 3
Completed	A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy NCT04291781	RemeGen Co., Ltd.	Phase 2
Completed	A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor NCT04014335	Ionis Pharmaceuticals, Inc.	Phase 2
Completed	Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy NCT03643965	Calliditas Therapeutics AB	Phase 3
Unknown	Integrative Medicine of IgA Nephropathy NCT02712697	Shanghai University of Traditional Chinese Medicine	N/A
Unknown	Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy NCT02765594	Peking Union Medical College Hospital	Phase 4
Completed	Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled S NCT02351752	LLiu	Phase 4
Recruiting	Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy NCT07074951	St. Petersburg State Pavlov Medical University	N/A
Completed	The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease NCT01738035	Calliditas Therapeutics AB	Phase 2